SEC Comment Letter for Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — May 18, 2021
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: May 18, 2021 · CIK: 0001506251 · Accession: 0000000000-21-006298
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-256063
Letter
United States securities and exchange commission logo May 18, 2021 Myron Holubiak President and Chief Executive Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 Re:Citius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 13, 2021 File No. 333-256063 Dear Mr. Holubiak: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alexander M. Donaldson
Show Raw Text
United States securities and exchange commission logo
May 18, 2021
Myron Holubiak
President and Chief Executive Officer
Citius Pharmaceuticals, Inc.
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
Re:Citius Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 13, 2021
File No. 333-256063
Dear Mr. Holubiak:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alexander M. Donaldson